Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Executive Summary
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.
You may also be interested in...
Merck Suggests More IO/ADC Combos To Come Under Oncology Strategy
The company laid out a three-pronged strategy focused on immuno-oncology, antibody-drug conjugates as well as small molecules, with four programs set to enter pivotal trials this year.
ImmunoGen’s Elahere Wins Big In Confirmatory Ovarian Cancer Trial
The company called MIRASOL’s reported OS benefit unprecedented and is gearing up to file for full FDA approval as well as EMA approval.
Exkivity Withdrawal Is Blow To Takeda’s Oncology Ambitions
The withdrawal of the targeted anticancer comes as no surprise after its Phase III missed in July, but it sets back Takeda’s expansion plans in the competitive therapy area.